✦ LIBER ✦

801 TIME TO PROGRESSION SHOULD NOT BE USED TO INFER THE ULTIMATE BENEFIT OF IMMEDIATE VERSUS DEFERRED/SALVAGE ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER

✍ Scribed by U.E. Studer; P. Whelan; F. Wimpissinger; J. Casselman; Th.M. De Reijke; H. Knönagel; S. Madersbacher; S. Isorna; S.K. Sundaram; L. Collette

Book ID: 119623139
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 221 KB
Volume: 10
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(11)60788-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

352 TIME TO DISEASE PROGRESSION IS NOT A

352 TIME TO DISEASE PROGRESSION IS NOT AN APPROPRIATE ENDPOINT IN STUDIES OF IMMEDIATE VERSUS DEFERRED/SALVAGE ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER

✍ Studer, Urs; Whelan, Peter; Wimpissinger, Florian; Casselman, Jacques; De Reijke 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 153 KB

Differences in Time to Disease Progressi

Differences in Time to Disease Progression Do Not Predict for Cancer-specific Survival in Patients Receiving Immediate or Deferred Androgen-deprivation Therapy for Prostate Cancer: Final Results of EORTC Randomized Trial 30891 with 12Years of Follow-up

✍ Kibel, A.S. 📂 Article 📅 2014 🏛 Elsevier Science ⚖ 46 KB